TL;DR
FDA-approved weight loss drugs include Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and orlistat products. Ozempic and Mounjaro have diabetes indications, not chronic weight-management indications. The right option depends on the label, health history, side effects, access, and total monthly cost.
FDA-approved weight loss drugs: The current list
Updated October 3, 2026. Drug labels can change. We recommend checking the current FDA prescribing information before choosing or changing treatment.
This weight loss medication list separates chronic treatment, short-term appetite suppressants, and rare-disease treatment. A prescription still requires clinician review.
Chronic weight-management drugs
| Product | Generic name | Route and schedule | FDA-approved population | Intended duration | Main pivotal-trial period |
|---|---|---|---|---|---|
| Wegovy | Semaglutide | Weekly injection; product-specific titration | Adults and patients age 12 or older who meet label criteria | Chronic | 68 weeks in a key adult trial |
| Zepbound | Tirzepatide | Weekly injection; stepwise dose increases | Adults who meet label criteria; check the current label for additional indications | Chronic | 72 weeks in a key obesity trial |
| Saxenda | Liraglutide | Daily injection; five-week titration | Adults and certain patients age 12 or older who meet product-specific criteria | Chronic | 56 weeks in a key adult trial |
| Qsymia | Phentermine/topiramate ER | Daily pill | Adults and certain patients age 12 or older who meet label criteria | Chronic | 56 weeks in key trials |
| Contrave | Naltrexone/bupropion ER | Daily pills in divided doses after four-week titration | Adults who meet label criteria | Chronic | 56 weeks in key trials |
| Xenical | Orlistat 120 mg | Pill with each fat-containing main meal | Adults and patients age 12 or older | Chronic | One year or longer in key studies |
| Alli | Orlistat 60 mg | Over-the-counter pill with each fat-containing meal | Adults age 18 or older | Ongoing use under its OTC label | Product studies vary |
Pediatric approval is product-specific. An adult indication for one drug does not establish the same age range for another.
Short-term drugs and rare-disease treatment
Phentermine, benzphetamine, diethylpropion, and phendimetrazine have FDA-approved short-term weight-loss uses under specific labels. Many labels describe treatment as a few weeks. These stimulants require checks for blood pressure, heart rate, interactions, and misuse risk.
Setmelanotide, sold as Imcivree, treats obesity caused by certain confirmed genetic disorders. It is not a general treatment for common obesity. Eligibility depends on the exact diagnosis and current label.
What FDA approval means—and what it does not
Approval covers a named product, indication, population, dose form, manufacturing process, and label. It does not mean the drug suits every patient or that insurance must pay for it.
| FDA-approved brand | FDA-approved generic | Compounded prescription | Dietary supplement |
|---|---|---|---|
| FDA reviews the product and its labeled use | FDA reviews equivalence and manufacturing requirements | FDA does not approve the finished compounded drug | Not approved as an obesity drug |
| Uses an approved label | Uses an approved generic label | Made for a patient under applicable compounding rules | Cannot replace prescription review |
| Product-specific manufacturing controls apply | Approved facilities and controls apply | Oversight depends on pharmacy type and law | Quality and evidence vary |
| Prescription may be required | Prescription may be required | Prescription is generally required | Often sold without a prescription |
Federal shortage policies and enforcement rules can change. Check the FDA’s current drug shortage database and compounding notices on the day treatment is ordered.
Do not stop, switch, or restart a prescription based only on this article. A clinician may need to reduce the dose or repeat titration after a gap.
Ozempic and Mounjaro are not FDA approved for weight loss
Ozempic contains semaglutide. Its label covers type 2 diabetes and specified risk-reduction uses. Wegovy also contains semaglutide, but it is a separate product with weight-management indications, doses, and instructions.
Mounjaro contains tirzepatide and has a type 2 diabetes label. Zepbound contains tirzepatide and has weight-management indications. Off-label prescribing can be lawful, but it is not the same as FDA approval for weight loss.
Our guide to getting an Ozempic prescription and paying for treatment explains that distinction in more detail.
Compounded GLP-1 drugs are a separate category
| Check | FDA-approved product | Compounded GLP-1 |
|---|---|---|
| FDA approval | Yes, for listed uses | No |
| Prescription | Usually required | Required in applicable cases |
| Pharmacy oversight | FDA and state systems apply | Depends on pharmacy type and jurisdiction |
| Ingredient form | Defined in the approved application | Must be confirmed |
| Dosing device | Labeled pen, tablet, or other approved form | May use a multi-dose vial and syringe |
| Availability | Based on approval and supply | Depends on current federal and state rules |
Compounded products are not automatically unsafe. They also are not approved generics. Risks may include unapproved salt forms, unclear sourcing, counterfeit stock, poor temperature control, or confusion between milligrams and syringe units.
Before paying, confirm:
- Pharmacy name and license
- Active ingredient and chemical form
- Concentration
- Dose in milligrams
- Syringe units, if used
- Storage and shipping method
- Beyond-use date
- Contact for adverse-event reports
Wegovy vs Zepbound vs Saxenda
Wegovy and Zepbound are weekly injections. Saxenda is daily. Each uses gradual dose increases, but the dose steps, pens, missed-dose rules, and storage instructions differ.
In pivotal adult trials, Wegovy produced about 14.9% mean weight loss at 68 weeks versus 2.4% with placebo. Zepbound’s highest studied dose produced about 20.9% at 72 weeks versus 3.1% with placebo. Saxenda produced about 8% at 56 weeks versus 2.6% with placebo.
These were not head-to-head trials. Participants, diabetes status, diet plans, discontinuation rules, and follow-up differed. See our separate guides to Wegovy results by month and Saxenda doses, costs, results, and safety.
Common effects include nausea, vomiting, diarrhea, constipation, and stomach pain. Product labels also address gallbladder disease, pancreatitis, pregnancy, severe stomach problems, and specific contraindications. Thyroid tumor contraindications apply to these products as stated in their labels.
Which injection showed the highest average trial weight loss?
Among the pivotal trials summarized above, the highest mean was reported with Zepbound 15 mg in adults without diabetes over 72 weeks. This is trial context, not a promise.
The highest average does not make one drug the right choice for every patient. A patient must tolerate it, meet label criteria, obtain it, and keep paying for it.
What happens after treatment stops?
Weight regain is common after anti-obesity medication stops. Follow-up and withdrawal studies show that drug effects often fade when treatment ends.
We recommend planning for maintenance before starting. That plan may include long-term medication, nutrition support, activity, follow-up, or a clinician-led change in treatment.
FDA-approved weight loss pills: Qsymia, Contrave, and orlistat
| Pill | Schedule | Relative trial effect | Food rules | Main limits |
|---|---|---|---|---|
| Qsymia | Once daily | Often greater than older oral options in separate trials | Follow label timing | Pregnancy risk, increased heart rate, stimulant effects, mood and cognitive effects |
| Contrave | Twice daily after titration | Moderate average effect | Avoid high-fat meals | Uncontrolled blood pressure, seizure risk, opioid use and interactions |
| Orlistat | With fat-containing meals | More modest average effect | Skip if the meal has no fat | Oily stool, urgency, vitamin absorption and drug interactions |
Qsymia must not be used during pregnancy. Some patients need a gradual taper rather than an abrupt stop, particularly at the highest dose.
Contrave contains bupropion and carries the antidepressant-class boxed warning about suicidal thoughts and behavior in younger patients. It can raise blood pressure and cannot be combined with opioid use in several common situations. Our Contrave dosing and 12-week response guide explains its stopping test.
Orlistat blocks part of dietary fat absorption. Patients may need a multivitamin containing fat-soluble vitamins, taken apart from the drug. Xenical is prescription strength. Alli is a lower-dose OTC product.
What is the best FDA-approved weight loss pill?
No pill is best for every patient. Qsymia may offer a stronger average effect, but it includes a stimulant and has strict pregnancy safeguards. Contrave avoids injections but conflicts with opioid use and certain seizure or blood pressure risks.
Orlistat has generic options and no stimulant action. Its bowel effects and meal-based dosing can limit adherence. The useful comparison is medical fit plus total cost, not average weight loss alone.
Short-term appetite suppressants are not the same as chronic treatment
Short-term appetite suppressants should not be presented as direct substitutes for chronic weight-management drugs. Their labels, treatment periods, evidence, and monitoring needs differ.
A prescriber should check blood pressure, heart rate, substance-use history, and interactions. “Short term” does not make a drug low risk.
Who may qualify for prescription weight loss treatment?
Many adult obesity-drug labels use these thresholds:
- BMI of at least 30
- BMI of at least 27 with at least one weight-related condition
Possible conditions include high blood pressure, abnormal cholesterol, type 2 diabetes, or obstructive sleep apnea. The exact wording varies by product. Meeting a threshold does not guarantee a prescription or insurance approval.
Pregnancy, age, current drugs, prior reactions, eating-disorder history, organ function, and product-specific contraindications also matter. Payment for a visit does not guarantee that a clinician will prescribe the requested drug.
What a clinician reviews before prescribing
A clinician may review:
- Medical and surgical history
- Current medicines and supplements
- Prior weight treatments
- Blood pressure and other vital signs
- Pregnancy status
- Current symptoms and side effects
- Relevant laboratory results
Lab needs vary. The drug, health history, symptoms, and care protocol determine which tests are needed.
Results, side effects, and reasons to stop or call for help
Trial averages require context. The result should name the dose, population, study length, and placebo result. Individual results may be higher, lower, or absent.
Common symptoms include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Contact a clinician promptly for persistent vomiting, dehydration, severe abdominal pain, allergic reaction signs, or another severe or worsening symptom.
Use the current FDA prescribing information for Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and orlistat products. Search by product name to obtain the latest label and Medication Guide.
Trial averages do not predict one person's result
Results depend on adherence, the dose reached, side effects, medical conditions, food intake, activity, and the study population. Stopping early also changes the result.
Avoid direct rankings when the evidence comes from separate trials. Head-to-head evidence gives a clearer comparison than unrelated percentages.
Missed doses and treatment gaps
Do not double a dose unless the product instructions specifically direct it. Missed-dose windows differ by drug.
After several missed weekly doses, contact the prescriber before restarting the old dose. Restarting too high may cause more side effects. The clinician may repeat part of the titration.
Cash price, insurance denials, and the real monthly cost
A useful price quote needs a date, dose, quantity, and supply period. A list price is not the same as a pharmacy cash price, insurance copay, coupon price, or savings-card price.
Prices change too often to publish one undated number as the cost. For any October 2026 quote, request these separate rows:
| Cost item | What to confirm |
|---|---|
| Medication | Product, dose, quantity, and 28- or 30-day supply |
| Clinical care | First visit and recurring visits |
| Membership | Introductory and recurring fee |
| Labs | Included tests and outside-lab charges |
| Shipping | Standard and expedited costs |
| Prior authorization | Included support and appeal limits |
| Refills | Processing or clinician-review fees |
| Cancellation | Deadline, refund rules, and commitments |
Commercial insurance, government coverage, and uninsured savings programs use different rules. Eligibility can change. A plan may also impose an exclusion, step therapy, or prior authorization.
The membership fee is not the treatment price
A $0 or low introductory membership does not establish the monthly treatment cost. Add the medicine, visits, labs, shipping, refill charges, and any dose-based price changes.
At Temi, we recommend checking the full checkout terms and current service details before paying. Published fees must match the patient’s state, requested service, pharmacy route, and current terms.
Lower-cost routes to ask about
Ask about:
- FDA-approved generics when available
- Prices at more than one licensed pharmacy
- A formulary exception or appeal
- Manufacturer programs
- A different approved drug that fits the same treatment goal
Compounded drugs belong on a separate decision path. They are not FDA-approved generic substitutes for Wegovy or Zepbound.
How online prescribing, refills, labs, and follow-up work
Online care usually follows this path:
- Intake and identity check
- Patient-location and clinician-license check
- Medical record review
- Prescription decision
- Pharmacy fulfillment
- Titration and follow-up
- Refill review
Service depends on clinician licensure, the patient’s location, pharmacy rules, and product supply. If the clinician declines a requested drug or dose, the next step may be a different dose, another product, more records, lab work, or no prescription.
A transfer patient may need the current prescription, product source, dose, last dose date, side effects, response, and recent labs. We do not promise uninterrupted stock or approval of the same dose after a treatment gap.
Refill checklist for current GLP-1 patients
Confirm:
- Product and manufacturer
- Pharmacy
- Dose in milligrams
- Pen strength or vial concentration
- Syringe units, if applicable
- Last dose date
- Remaining doses
- Missed doses
- Side effects
- Last relevant lab date
- Refill deadline
- Prior authorization expiration
How to reduce an avoidable treatment gap
Request refills before the stated cutoff. Keep the prescriber and pharmacy contact information current.
Report side effects, denials, and supply problems early. Do not raise the dose or restart after a long gap without instructions.
New 2026 pills, celebrity claims, and other common questions
A positive trial does not equal FDA approval. The steps are distinct: trial result, application submission, FDA acceptance, approval, and commercial launch.
The same rule applies to oral tirzepatide claims. Our guide to tirzepatide pills and oral alternatives separates approved products from candidates and unverified sellers.
How much is the new Wegovy pill?
First confirm that the exact oral product has an FDA approval record and has launched. Do not use injectable Wegovy’s price or the price of diabetes-labeled oral semaglutide as a substitute.
A valid quote must name the oral product, strength, tablet count, supply period, source, and date. No price should be inferred for an unapproved or unlaunched drug.
What is the new weight loss pill coming out in 2026?
Several oral obesity drugs have been studied, including oral semaglutide and oral GLP-1 candidates. A submitted application or successful trial does not establish approval or a 2026 launch.
Check Drugs@FDA for the exact product and approval date. Manufacturer forecasts should not be treated as final FDA decisions.
What did Kelly Clarkson use to lose weight?
Kelly Clarkson has publicly discussed using a prescription medicine, but public comments have not supplied the full clinical record needed to guide another person’s care. Photos and rumors do not establish the exact product, dose, diagnosis, or treatment plan.
Celebrity experience cannot replace label review and medical screening. Treatment should be based on the patient’s history, risks, and access.
FAQ
What is the best weight loss pill FDA approved?
There is no best pill for everyone. Qsymia may produce greater average loss than some older pills, but stimulant effects and pregnancy risk can rule it out. Contrave conflicts with opioid use and some seizure risks. Orlistat may cost less, but bowel effects and meal dosing can be hard to maintain.
Is Ozempic an FDA-approved weight loss drug?
No. Ozempic is FDA approved for type 2 diabetes and specified related risk-reduction uses, not chronic weight management. Wegovy contains the same active ingredient, semaglutide, but has separate weight-management indications, doses, and instructions. Off-label Ozempic prescribing does not change the FDA label.
How much is the new Wegovy pill?
The answer depends on whether the exact oral Wegovy product is FDA approved and commercially available on the date of the quote. Do not substitute injectable Wegovy pricing. Confirm the product, dose, tablet count, supply period, list price, cash price, coverage terms, and quote date.
What is the new weight loss pill coming out in 2026?
No drug should be described as “coming out” until its approval and launch are verified. Oral semaglutide and other oral obesity candidates have been studied. Trial success, an FDA filing, and FDA acceptance are not approval. Check Drugs@FDA and the manufacturer’s dated regulatory notice.
Are compounded GLP-1 drugs FDA approved?
No. The FDA does not approve compounded drugs. A compounded prescription may be legally available in a specific case under current rules, but that does not prove equivalence to an approved brand. Confirm the pharmacy, ingredient form, concentration, milligrams, syringe units, storage, and beyond-use date.
Review your next prescription or refill
Use Temi’s online prescription platform to submit your history and current treatment details for clinician review. A prescription is not guaranteed, but a complete intake can reduce delays caused by missing dose, refill, pharmacy, or lab information.
